Navigation Links
New opportunity for rapid treatment of malaria
Date:10/25/2012

Researchers have identified a new means to eradicate malaria infections by rapidly killing the blood-borne Plasmodium parasites that cause the disease.

Malaria causes up to 3 million deaths each year, predominantly afflicting vulnerable people such as children under five and pregnant women, in tropical regions of Africa, Asia, and Latin America. Treatments are available for this disease, but the Plasmodium parasite is fast becoming resistant to the most common drugs, and health authorities say they desperately need new strategies to tackle the disease.

This new potential treatment uses molecules that interfere with an important stage of the parasite's growth cycle and harnesses this effect to kill them. The impact is so acute it kills ninety per cent of the parasites in just three hours and all those tested in laboratory samples of infected human blood cells, within twelve hours.

The research was carried out by chemists at Imperial College London and biological scientists from the research institutions Institut Pasteur and CNRS in France. Their work is published in the journal Proceedings of the National Academy of Sciences (PNAS).

Lead researcher Dr Matthew Fuchter, from Imperial College London, said: "Plasmodium falciparum causes 90 per cent of malaria deaths, and its ability to resist current therapies is spreading dramatically. Whilst many new drugs are in development, a significant proportion are minor alterations, working in the same way as current ones and therefore may only be effective in the short term. We believe we may have identified the parasite's 'Achilles' Heel', using a molecule that disrupts many vital processes for its survival and development."

The research has identified two chemical compounds that affect Plasmodium falciparum's ability to carry out transcription, the key process that translates genetic code into proteins. These compounds are able to kill the parasite during the long period of its complex life cycle while it inhabits the blood-stream. This is in contrast to the majority of antimalarial drugs, whose action is limited to shorter stages of Plasmodium's life cycle.

"One particularly exciting aspect of this discovery is this new molecule's ability to rapidly kill off all traces of the parasite, acting at least as fast as the best currently available antimalarial drug," said Dr Fuchter.

Initial tests also showed the molecules were able to kill strains of Plasmodium that have developed a resistance to current treatments, although the scientists say more experiments are needed to confirm these results.

The scientists hope to refine these molecules, improving their effectiveness and proving this to be a viable strategy for treating malaria in humans. They hope it will lead to the development of an effective malaria cure within the next ten years.


'/>"/>
Contact: Simon Levey
s.levey@imperial.ac.uk
44-020-759-46702
Imperial College London
Source:Eurekalert

Related medicine news :

1. LA BioMed offers unique educational and research opportunity to local high school seniors
2. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
3. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
4. Obesity in Middle Age Tied to More Rapid Mental Decline: Study
5. Strawberry birthmarks grow rapidly when babies just weeks old, Mayo Clinic finds
6. UGA researchers develop rapid diagnostic test for pathogens, contaminants
7. OnPage Provides Secure, Rapid Response at New England’s Largest Catholic Hospital
8. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
9. Rapid Asthma Treatment in ER May Prevent Admission
10. Satellite observes rapid ice shelf disintegration in Antarctic
11. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: